tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

GlucoTrack Inc

GCTK
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
0.320USD
-0.028-7.97%
์ข…๊ฐ€ย 07/02, 13:00๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
291.42K์‹œ๊ฐ€์ด์•ก
0.05P/E TTM
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
TradingKey ๅ›พ่กจ
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

-7.97%

5์ผ

-3.03%

1๊ฐœ์›”

-51.88%

6๊ฐœ์›”

-91.75%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

-91.73%

1๋…„

-95.17%

ํ•ต์‹ฌ ์ˆ˜์น˜
0.338์‹œ๊ฐ€
0.346์ตœ๊ณ ๊ฐ€
74.27K๊ฑฐ๋ž˜๋Ÿ‰
0.05P/E TTM
--๋™์  P/E ๋น„์œจ
--๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
8.16%ํšŒ์ „์œจ
0.348์ „์ผ ์ข…๊ฐ€
0.320์ตœ์ €๊ฐ€
19.41K๋งค์ถœ์•ก
์†์‹ค์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
0.10P/B
0.00%๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
-241.82%ROA
15.90052์ฃผ ์ตœ๊ณ ๊ฐ€
0.92๊ฑฐ๋ž˜๋Ÿ‰ ๋น„์œจ
-22.60M์ˆœ์ด์ต
910.69K์ฃผ์‹
6.4878์ฃผ๋‹น์ˆœ์ด์ต
0.70๋ฒ ํƒ€
-527.20%ROE
0.61952์ฃผ ์ตœ์ €๊ฐ€
7.48%๋ณ€๋™ ํญ
--์ด ์ด์ต๋ฅ 
291.42K์‹œ๊ฐ€์ด์•ก
-6.49๋ณด์ƒ/์œ„ํ—˜
7.35%์œ„ํ—˜๋ฅ 

TradingKey GlucoTrack Inc ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2026-07-02

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

GlucoTrack Inc์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•„์ฃผ ๊ฑด์ „ํ•œ ์ƒํƒœ์ด๋ฉฐ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ ์‚ฐ์—…์—์„œ 387๊ฐœ ์ค‘ 225์œ„ ๋žญํ‚น.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ํ•˜๋ฝ ์ถ”์„ธ์ผ ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ๋งค์šฐ ๋ถ€์ง„ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘์—ˆ์ง€๋งŒ, ๊ธฐ์—…์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ํƒ„ํƒ„ํ•ฉ๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

GlucoTrack Inc ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
225 / 387
์ „์ฒด ์ˆœ์œ„
460 / 4565
์‚ฐ์—…
์ƒ๋ช…๊ณตํ•™ ๋ฐ ์˜๋ฃŒ ์—ฐ๊ตฌ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ฏธ๋””์–ด ๋ณด๋„

์ตœ๊ทผ 24 ์‹œ๊ฐ„
๋ณด๋„ ์ˆ˜์ค€

๋งค์šฐ ๋‚ฎ์€
๋งค์šฐ ๋†’์€
์ค‘๋ฆฝ

GlucoTrack Inc ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
๊ณ ์ˆ˜์ต ์„ฑ์žฅ
ํšŒ์‚ฌ์˜ ์ˆœ์ด์ต์€ ์—…๊ณ„ ์„ ๋‘๋ฅผ ๋‹ฌ๋ฆฌ๊ณ  ์žˆ์œผ๋ฉฐ, ์ตœ๊ทผ ์—ฐ๊ฐ„ ์ˆœ์ด์ต์€ ๋ฏธํ™” 0.00์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณผ๋Œ€ ํ‰๊ฐ€๋œ
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ 0.05๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ๋†’์€ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค์ˆ˜
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 221.24K์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 31.18% ์ฆ๊ฐ€ํ–ˆ์Šต๋‹ˆ๋‹ค.

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

0 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
--
ํ˜„์žฌ ๋“ฑ๊ธ‰
--
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
--
์ƒ์Šน ์—ฌ๋ ฅ

GlucoTrack Inc ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

GlucoTrack Inc ์ •๋ณด๎˜

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
์ข…๋ชฉ ์ฝ”๋“œ GCTK
ํšŒ์‚ฌGlucoTrack Inc
CEOGoode (Paul V)
์›น์‚ฌ์ดํŠธhttps://glucotrack.com/

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

GlucoTrack Inc(GCTK)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
GlucoTrack Inc(GCTK)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 0.32์ž…๋‹ˆ๋‹ค.

GlucoTrack Inc์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
GlucoTrack Inc์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” GCTK์ž…๋‹ˆ๋‹ค.

GlucoTrack Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
GlucoTrack Inc์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 15.90์ž…๋‹ˆ๋‹ค.

GlucoTrack Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
GlucoTrack Inc์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 0.62์ž…๋‹ˆ๋‹ค.

GlucoTrack Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
GlucoTrack Inc์˜ ์‹œ๊ฐ€์ด์•ก์€ 291.42K์ž…๋‹ˆ๋‹ค.

GlucoTrack Inc(GCTK)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
GlucoTrack Inc(GCTK)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ -31.22์ž…๋‹ˆ๋‹ค.